- Home
- NUTX vs CLLS Comparison
NUTX vs CLLS Comparison
Compare NUTX & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUTX
- CLLS
- Stock Information
- Founded
- NUTX 2011
- CLLS 1999
- Country
- NUTX United States
- CLLS France
- Employees
- NUTX N/A
- CLLS 216
- Industry
- NUTX Retail: Computer Software & Peripheral Equipment
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- NUTX Technology
- CLLS Health Care
- Exchange
- NUTX Nasdaq
- CLLS Nasdaq
- Market Cap
- NUTX 182.2M
- CLLS 148.1M
- IPO Year
- NUTX N/A
- CLLS 2007
- Fundamental
- Price
- NUTX $37.81
- CLLS $1.48
- Analyst Decision
- NUTX Strong Buy
- CLLS Buy
- Analyst Count
- NUTX 2
- CLLS 3
- Target Price
- NUTX $55.00
- CLLS $7.00
- AVG Volume (30 Days)
- NUTX 25.0K
- CLLS 235.1K
- Earning Date
- NUTX 11-07-2024
- CLLS 11-04-2024
- Dividend Yield
- NUTX N/A
- CLLS N/A
- EPS Growth
- NUTX N/A
- CLLS N/A
- EPS
- NUTX N/A
- CLLS N/A
- Revenue
- NUTX $292,000,390.00
- CLLS $36,042,000.00
- Revenue This Year
- NUTX $25.00
- CLLS $387.77
- Revenue Next Year
- NUTX $14.40
- CLLS $11.14
- P/E Ratio
- NUTX N/A
- CLLS N/A
- Revenue Growth
- NUTX 26.02
- CLLS 46.96
- 52 Week Low
- NUTX $4.16
- CLLS $1.41
- 52 Week High
- NUTX $41.44
- CLLS $3.38
- Technical
- Relative Strength Index (RSI)
- NUTX 63.48
- CLLS 38.66
- Support Level
- NUTX $28.82
- CLLS $1.65
- Resistance Level
- NUTX $35.94
- CLLS $2.23
- Average True Range (ATR)
- NUTX 2.18
- CLLS 0.18
- MACD
- NUTX 0.47
- CLLS -0.03
- Stochastic Oscillator
- NUTX 77.57
- CLLS 8.54
About NUTX Nutex Health Inc.
Nutex Health Inc is healthcare services and operations company with 20 hospital facilities in eight states (hospital division), and a primary care-centric, risk-bearing population health management division. The hospital division implements and operates healthcare models, including micro-hospitals, specialty hospitals and hospital outpatient departments (HOPDs). The population health management division owns and operates provider networks such as independent physician associations (IPAs) and offers a cloud-based proprietary technology platform to IPAs that aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.